Response rate (complete and partial response) Up to 3 years [clinicaltrials_resource:78d06bf5cb89025da727fca8f85ec30f]
Patients receive tanespimycin IV over 1-6 hours once weekly for 6 weeks. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Response rate (complete and partial response) Up to 3 years [clinicaltrials_resource:78d06bf5cb89025da727fca8f85ec30f]
Patients receive tanespimycin IV over 1-6 hours once weekly for 6 weeks. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
Bio2RDF identifier
78d06bf5cb89025da727fca8f85ec30f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:78d06bf5cb89025da727fca8f85ec30f
measure [clinicaltrials_vocabulary:measure]
Response rate (complete and partial response)
time frame [clinicaltrials_vocabulary:time-frame]
Up to 3 years
description
Patients receive tanespimycin ...... sion or unacceptable toxicity.
identifier
clinicaltrials_resource:78d06bf5cb89025da727fca8f85ec30f
title
Response rate (complete and partial response) Up to 3 years
@en
type
label
Response rate (complete and pa ...... 06bf5cb89025da727fca8f85ec30f]
@en